A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer's Disease

被引:16
|
作者
Xu, Chang [1 ]
Zhao, Li [1 ]
Dong, Chunbo [1 ]
机构
[1] Dalian Med Univ, Affiliated Hosp 1, Dept Neurol, Dalian, Peoples R China
关键词
Alzheimer's disease; amyloid-beta; biomarker; cerebrospinal fluid; plasma; PLASMA AMYLOID-BETA; DIFFERENTIAL DEMENTIA DIAGNOSIS; CEREBROSPINAL-FLUID BIOMARKERS; MILD COGNITIVE IMPAIRMENT; A-BETA; BLOOD BIOMARKERS; A-BETA(42)/A-BETA(40) RATIO; A-BETA-42/A-BETA-40; RATIO; CSF A-BETA-42/A-BETA-40; CLINICAL-DIAGNOSIS;
D O I
10.3233/JAD-220673
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The number of patients with Alzheimer's disease (AD) and non-Alzheimer's disease (non-AD) has drastically increased over recent decades. The amyloid cascade hypothesis attributes a vital role to amyloid-beta protein (A beta) in the pathogenesis of AD. As the main pathological hallmark of AD, amyloid plaques consist of merely the 42 and 40 amino acid variants of A beta (A beta(42) and A beta(40)). The cerebrospinal fluid (CSF) biomarker A beta(42/40) has been extensively investigated and eventually integrated into important diagnostic tools to support the clinical diagnosis of AD. With the development of highly sensitive assays and technologies, blood-based A beta(42/40), which was obtained using a minimally invasive and cost-effective method, has been proven to be abnormal in synchrony with CSF biomarker values. This paper presents the recent progress of the CSF A beta(42/40) ratio and plasma A beta(42/40) for AD as well as their potential clinical application as diagnostic markers or screening tools for dementia.
引用
收藏
页码:495 / 512
页数:18
相关论文
共 50 条
  • [31] Clinical usefulness of the CSF β-amyloid Aβ1-42/Aβ1-40 ratio for Alzheimer's disease diagnosis: a retrospective study in a Belgian academic hospital
    Deltombe, Matthieu
    Fillee, Catherine
    van Pesch, Vincent
    ACTA NEUROLOGICA BELGICA, 2022, 122 (01) : 245 - 247
  • [32] Clinical usefulness of the CSF β-amyloid Aβ1-42/Aβ1-40 ratio for Alzheimer’s disease diagnosis: a retrospective study in a Belgian academic hospital
    Matthieu Deltombe
    Catherine Fillee
    Vincent van Pesch
    Acta Neurologica Belgica, 2022, 122 : 245 - 247
  • [33] Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale
    Lehmann, Sylvain
    Delaby, Constance
    Boursier, Guilaine
    Catteau, Cindy
    Ginestet, Nelly
    Tiers, Laurent
    Maceski, Aleksandra
    Navucet, Sophie
    Paquet, Claire
    Dumurgier, Julien
    Vanmechelen, Eugeen
    Vanderstichele, Hugo
    Gabelle, Audrey
    FRONTIERS IN AGING NEUROSCIENCE, 2018, 10
  • [34] Systemic catabolism of Alzheimer's Aβ40 and Aβ42
    Ghiso, J
    Shayo, M
    Calero, M
    Ng, D
    Tomidokoro, Y
    Gandy, S
    Rostagno, A
    Frangione, B
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (44) : 45897 - 45908
  • [35] A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
    Hedieh Shahpasand-Kroner
    Hans-W. Klafki
    Chris Bauer
    Johannes Schuchhardt
    Melanie Hüttenrauch
    Martina Stazi
    Caroline Bouter
    Oliver Wirths
    Jonathan Vogelgsang
    Jens Wiltfang
    Alzheimer's Research & Therapy, 10
  • [36] Differential Effects of Alzheimer's Disease Aβ40 and 42 on Endocytosis and Intraneuronal Trafficking
    Omtri, Rajesh S.
    Thompson, Kevin J.
    Tang, Xiaojia
    Gali, Chaitanya C.
    Panzenboeck, Ute
    Davidson, Michael W.
    Kalari, Krishna R.
    Kandimalla, Karunya K.
    NEUROSCIENCE, 2018, 373 : 159 - 168
  • [37] Plasma Aβ40 and Aβ42 and Alzheimer's disease -: Relation to age, mortality, and risk
    Mayeux, R
    Honig, LS
    Tang, MX
    Manly, J
    Stern, Y
    Schupf, N
    Mehta, PD
    NEUROLOGY, 2003, 61 (09) : 1185 - 1190
  • [38] Pathological Aβ42/Aβ40 predicts brain damage load in Alzheimer's Disease
    Di Donna, M.
    Bonomi, C.
    Aartorana, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 532 - 532
  • [39] Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls
    Xu, Wuhua
    Kawarabayashi, Takeshi
    Matsubara, Etsuro
    Deguchi, Kentaro
    Murakami, Tetsuro
    Harigaya, Yasuo
    Ikeda, Masaki
    Amari, Masakuni
    Kuwano, Ryozo
    Abe, Koji
    Shoji, Mikio
    BRAIN RESEARCH, 2008, 1219 : 169 - 179
  • [40] Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease
    Jonathan Vogelgsang
    Hedieh Shahpasand-Kroner
    Rebekka Vogelgsang
    Frank Streit
    Ruth Vukovich
    Jens Wiltfang
    Experimental Brain Research, 2018, 236 : 1241 - 1250